Product Information
PRALUENT 150 MG/ML PEN is a brand product labeled by Regeneron Pharmaceuticals, Inc., priced at $258.0073 per ML under NDC 61755002102. Its NADAC has been published 272 times since Jul 21, 2021.
Strength
150 mg/mL
Manufacturer
Regeneron Pharmaceuticals, Inc.NDC
61755002102
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
ALIROCUMABApproval Type
Biologic (BLA)
FDA Application
BLA125559On Market Since
12/1/2020
Pharmacological Classes
Price Statistics
The NADAC for PRALUENT 150 MG/ML PEN has been published 272 times since Jul 21, 2021, and over the history we have for it it has risen 18.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $258.0073 per ML |
|---|---|
| All-time high | $258.1639 (May 13, 2026) |
| All-time low | $217.5943 (Jul 21, 2021) |
| 52-week high | $258.1639 |
| 52-week low | $250.5934 |
| Median price | $243.9896 |
| Average price | $241.1671 |
| Largest weekly change | +3.0% (Jul 27, 2022) |
| Weeks tracked | 272 |
| Tracking since | Jul 21, 2021 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the alirocumab market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Regeneron Pharmaceuticals, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
alirocumab market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
PCSK9 Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PRALUENT 150 MG/ML PEN?
The current National Average Drug Acquisition Cost (NADAC) for PRALUENT 150 MG/ML PEN, manufactured by Regeneron Pharmaceuticals, Inc., is $258.0073 per ML (NDC 61755002102), effective Sep 30, 2026.
How has the price of PRALUENT 150 MG/ML PEN changed over time?
Over the history we have for it, the NADAC for PRALUENT 150 MG/ML PEN has risen 18.6%. It has been tracked across 272 weekly CMS publications since Jul 21, 2021.
What are the highest and lowest recorded NADAC prices for PRALUENT 150 MG/ML PEN?
Since Jul 21, 2021, the NADAC for PRALUENT 150 MG/ML PEN has ranged from a low of $217.5943 (Jul 21, 2021) to a high of $258.1639 (May 13, 2026), with a median of $243.9896 per ML.
Are there cheaper alternatives to PRALUENT 150 MG/ML PEN?
No other NADAC-published product currently shares the active ingredient and strength of PRALUENT 150 MG/ML PEN in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures PRALUENT 150 MG/ML PEN?
PRALUENT 150 MG/ML PEN (NDC 61755002102) is labeled by Regeneron Pharmaceuticals, Inc., and CMS classifies it as a brand product.